• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Invega (paliperidone), Invega Sustenna, Invega Trinza, Invega Hayfera

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Invega (paliperidone), Invega Sustenna, Invega Trinza, Invega Hayfera

  • Profile

Profile

Contact Information

Contact: Janssen Pharmaceuticals
Website: https://www.janssen.com/us/our-products

Currently Enrolling Trials

    Show More

    General Information

    Invega and its various formulations is an active metabolite of risperidone. It is an antagonist and thus interferes with neurotransmitter communication in the brain. It blocks dopamine type 2, serotonin type 2, and alpha 2 adrenergic receptors, all of which have been implicated in schizophrenia.

    Invega is specifically indicated for the treatment of schizophrenia as monotherapy and as an adjunct to mood stabilizers and/or antidepressants

    Invegga Sustenna (1-month injection) is specifically indicated for the treatment of schizophrenia in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants

    Invegga Trinza (3-month injection) is specifically indicated for the treatment of schizophrenia in patients after they have been adequately treated with Invegga Sustenna for at least four months.

    Invega Hayfera (every-six-month injection) is indicated for the treatment of schizophrenia in adults after they have been adequately treated with:

    • A once-a-month paliperidone palmitate extended-release injectable suspension (e.g., Invega Sustenna) for at least four months or
    • An every-three-month paliperidone palmitate extended-release injectable suspension (e.g., Invega Trinza) for at least one three-month cycle

    Invega is supplied as the following formulations: 

    • Invega (paliperidone extended-release (ER) tablets),
    • Invega Sustenna (1-month paliperidone palmitate extended-release injectable suspension)
    • Invega Trinza (3-month paliperidone palmitate)
    • Invega Hayfera (6-month paliperidone palmitate)

    Mechanism of Action

    Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone is unclear. However, the drug’s therapeutic effect in schizophrenia could be mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.

    Side Effects

    Adverse events associated with the use of Invega may include, but are not limited to, the following:

    • Parkinsonism
    • Akathisia
    • Dyskinesia
    • Tachycardia
    • Headache
    • Somnolence
    • Anxiety
    • Hyperkinesia
    • Extrapyramidal disorder
    • Dystonia

    The Invega drug labels all come with the following Black Box Warning: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. None of the Invega formulations are approved for use in patients with dementia-related psychosis.

    Clinical Trial Results

    FDA approval of Invega was based on the results of three clinical trials. These placebo-controlled, active-controlled (olanzapine), fixed-dose trials enrolled 1,665 non-elderly adult subjects who met DSM-IV criteria for schizophrenia, internationally. Subjects received placebo or Invega at 3, 6, 9, 12, and 15 mg/day for six weeks. Efficacy was evaluated using the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale. Results revealed all doses of Invega to be superior to placebo on both the PANSS and PSP scales. The mean effects at all doses were fairly similar, although the higher doses in all studies were numerically superior.

    The FDA approval of Invega Hayfera was based on the results of a 12-month, randomized, double-blind, non-inferiority Phase 3 global study that enrolled 702 adults (ages 18-70) living with schizophrenia from 20 countries. The results showed non-inferiority of INVEGA HAFYERA™ compared to Invega Trinza on the primary endpoint of time to first relapse at the end of the 12-month period. Results found that 92.5 percent of patients treated with Invega Hayfera and 95 percent treated with Invega Trinza were relapse-free at 12 months. Relapse was defined as psychiatric hospitalization, increase in Positive and Negative Syndrome Scale [PANSS] total score, increase in individual PANSS item scores, self-injury, violent behavior, or suicidal/homicidal ideation.

    Approval Date: 2006-12-01
    Company Name: Janssen Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing